Request Free Sample
×
Peptide Receptor Radionuclide Therapy Market
ID: MRFR/Pharma/35169-HCR
100 Pages
October 2025
Rapport d'étude de marché sur la thérapie radionucléide par récepteurs peptidiques PRRT par indication (tumeurs neuroendocrines, cancer de la prostate, phéochromocytome, tumeurs carcinoïdes gastriques), par type de thérapie (produits radiopharmaceutiques thérapeutiques, produits radiopharmaceutiques diagnostiques, thérapie combinée), par voie d'administration (intraveineuse, sous-cutanée), par utilisateur final (hôpitaux, cliniques spécialisées, instituts de recherche) et par région (Amérique du Nord, Europe, Sud). Amérique, Asie-Pac... lire la suite
Les principales entreprises du marché Peptide Receptor Radionuclide Therapy Market incluent
Portée du rapport
FAQs
What is the current market valuation of the Peptide Receptor Radionuclide Therapy (PRRT) market?
The Peptide Receptor Radionuclide Therapy market was valued at 2.848 USD Billion in 2024.
What is the projected market size for PRRT by 2035?
The market is expected to reach 7.335 USD Billion by 2035.
What is the expected CAGR for the PRRT market during the forecast period 2025 - 2035?
The expected CAGR for the PRRT market during 2025 - 2035 is 8.98%.
Which companies are the key players in the PRRT market?
Key players in the PRRT market include Novartis, Bayer, Ipsen, Advanced Accelerator Applications, Lantheus Medical Imaging, TheraP, Siemens Healthineers, and GE Healthcare.
What are the primary indications for PRRT?
The primary indications for PRRT include Neuroendocrine Tumors, Prostate Cancer, Pheochromocytoma, and Gastric Carcinoid Tumors.
How is the PRRT market segmented by type of therapy?
The PRRT market is segmented into Therapeutic Radiopharmaceuticals, Diagnostic Radiopharmaceuticals, and Combination Therapy.
What are the projected revenues for Neuroendocrine Tumors in the PRRT market by 2035?
Revenues for Neuroendocrine Tumors are projected to reach 3.675 USD Billion by 2035.
What is the expected revenue for hospitals as end users of PRRT by 2035?
Hospitals are expected to generate revenues of 3.675 USD Billion as end users of PRRT by 2035.
What administration routes are utilized in the PRRT market?
The PRRT market utilizes both Intravenous and Subcutaneous administration routes.
How does the revenue for specialized clinics compare to hospitals in the PRRT market by 2035?
By 2035, specialized clinics are projected to generate 2.215 USD Billion, which is significantly lower than the 3.675 USD Billion expected for hospitals.
Télécharger l'échantillon gratuit
Veuillez remplir le formulaire ci-dessous pour recevoir un échantillon gratuit de ce rapport
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Étude de cas
Aerospace & Defense
Laisser un commentaire